Dietary intervention using the food for special medical purposes in question to address specific nutrient deficiencies has a positive effect on cognitive performance in patients with early Alzheimer’s Disease.
ID
Bron
Verkorte titel
Aandoening
Alzheimer Disease
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Cognitive Performance at 12 weeks.
Achtergrond van het onderzoek
The investigational test product is developed for the dietary management of Alzheimer’s disease. Patients with early Alzheimer’s Disease will be randomized in this parallel, double-blinded study to use the test product for an intervention period of 12 weeks (with a possible extension of another 12 weeks). Cognitive performance, behaviour, functional abilities, Quality of Life and blood parameters will be evaluated at regular intervals (weeks 3, 6, 12, 18, 24) throughout the intervention period. The patient’s caregiver will support the patient during the study and during the visits and s/he will be interviewed as well.
Doel van het onderzoek
Dietary intervention using the food for special medical purposes in question to address specific nutrient deficiencies has a positive effect on cognitive performance in patients with early Alzheimer’s Disease.
Onderzoeksopzet
N/A
Onderzoeksproduct en/of interventie
Duration intervention: 12 weeks, with possible extension of 12 weeks.
Intervention group: all participants in the intervention group will receive daily 125 ml of a nutritional supplementation, containing particular nutrients that are expected to have a positive effect on cognitive performance in patients with early Alzheimer’s Disease.
Control group: all participants in the control group will receive daily 125 ml of an isocaloric nutritional supplementation, without the nutrients that have been added to the active study product.
Publiek
PO Box 7005
Patrick Kamphuis
Wageningen 6700 CA
The Netherlands
+31 (0)317 467 800
Patrick.Kamphuis@Numico-Research.nl
Wetenschappelijk
PO Box 7005
Patrick Kamphuis
Wageningen 6700 CA
The Netherlands
+31 (0)317 467 800
Patrick.Kamphuis@Numico-Research.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Out-patients, age >= 50 yrs;
2. Diagnosis of probable Alzheimer Disease according to the NINCDS-ADRDA criteria;
3. MRI or CT scan compatible with diagnosis of Alzheimer’s Disease within 2 yr prior to inclusion;
4. MMSE score between 20-26 (inclusive);
5. Hachinski Ischemia Scale Score =< 4;
6. No depressive symptoms (GDS =< 4);
7. Females are postmenopausal or surgically sterile;
8. Availability of caregiver;
9. Written informed consent from patient and caregiver.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Vascular dementia;
2. History, or expected need during the study of cholinesterase-inhibitors or NMDA-receptor antagonists or medications with cholinergic or anticholinergic side effects;
3. Use of specific antidepressants, tranquilizers and lipid lowering medications if not on stable use for at least three months prior to baseline;
4. (Expected) Use of specific (doses of) nutritional supplements;
5. Presence of Down Syndrome;
6. Investigator’s uncertainty about the willingness or ability of the patient to comply with the protocol requirements;
7. Participation in any other studies involving investigational or marketed products concomitantly or within eight weeks prior to baseline;
8. Excessive alcohol intake or drug abuse.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL642 |
| NTR-old | NTR702 |
| Ander register | : Protocol Number 60.44 |
| ISRCTN | ISRCTN72254645 |
Samenvatting resultaten
Philip Scheltensa,*, Patrick J. G. H. Kamphuisb, Frans R. J. Verheyc, Marcel G. M. Olde Rikkertd, Richard J. Wurtmane, David Wilkinsonf, Jos W. R. Twiskg, Alexander Kurzh.
<br><br>
EFFICACY OF A MEDICAL FOOD ON COGNITION IN ALZHEIMER’S DISEASE: RESULTS FROM SECONDARY ANALYSES OF A RANDOMIZED, CONTROLLED TRIAL. J Nutr Health Aging. 2011 15(8):720-4 <br>P.J.G.H. KAMPHUIS, F.R.J. VERHEY, M.G.M. OLDE RIKKERT, J.W.R. TWISK, S.H.N. SWINKELS, P. SCHELTENS
<br><br>
Effect of a medical food on Body Mass Index and activities of daily living in patients with Alzheimer’s disease: secondary analyses from a randomized, controlled trial. J Nutr Health Aging. 2011 15(8), 672-676.<br>
P.J.G.H. kamphuis, F.R.J. verhey, M.G.M. Olde Rikkert, J.W.R. Twisk, S.H.N. Swinkels, P. Scheltens.